Fact CheckerSign in

NCT07746271Not yet recruitingPhase 3

Gestational Hypertension and Preeclampsia Blood Pressure (BP) Treatment Goals Less Than 140/90 vs. Less Than 160/110 mmHg: The GOALPOST Trial

Source: ClinicalTrials.gov · Last updated 18 Sept 2026

Brief summary (registry, in English)

This is a phase-III multi-center open-label randomized clinical trial of 4,120 individuals between 23 weeks, 0 days and 35 weeks, 6 days gestation with gestational hypertension or preeclampsia without severe features randomized to antihypertensive medication to a target blood pressure (BP) of \<140/90 mmHg or to no treatment for non-severe hypertension \< 160/110 mmHg (usual care). The primary endpoint is an adverse pregnancy composite comprised of preeclampsia with end-organ damage, medically indicated preterm delivery \<37 weeks 0 days gestation, fetal/neonatal/infant death, or placental abruption.

Status (registry)
Not yet recruiting
Phase (registry)
Phase 3
Study type
Interventional
Enrollment
4120 (estimated)
First submitted
28 Jul 2026
Start date
30 Sept 2026
Primary completion date
31 Dec 2029
Lead sponsor
The George Washington University Biostatistics Center
NCT number
NCT07746271

What you commit to

  • Study type: Interventional · Phase 3
  • Planned participants: 4120
  • From 30 Sept 2026 to the primary completion date, 31 Dec 2029
  • 14 sites in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Two blood pressure measurements ≥ 140/90 at least 4 hours apart prior to 20 weeks 0 days in the current pregnancy
  • History or current use of anti-HTN medication defined as any of the following:
    • Prescribed anti-HTN medication for the indication of lowering blood pressure within 12 months prior to conception or prior to 20 weeks 0 days in the current pregnancy. Use during a prior pregnancy and through 12 weeks postpartum, or use for stage 1 chronic hypertension is not an exclusion.
    • Current use of anti-HTN medication. Participants on anti-HTN medication for the purpose of treating non-severe hypertensive disorders of pregnancy, or for indications other than hypertension, who are willing to go through a 48 hour washout before randomization would be eligible.
  • Eclampsia
    • Oligohydramnios defined as a maximum vertical pocket (MVP) \<2 cm or an amniotic fluid index (AFI) \< 5 cm
    • Fetal growth restriction defined as estimated fetal weight \< 5th percentile, or fetal growth restriction \<10th percentile (estimated fetal weight \<10th percentile or abdominal circumference \< 10th percentile) with abnormal umbilical artery dopplers (elevated (S/D ratio \>95th percentile for gestational age), absent or reversed end diastolic flow)
    • Known fetal genetic disease or major malformations
    • Fetal demise or planned termination of pregnancy.
    • Planned indicated delivery prior to 37 weeks 0 days
    • Participation in another interventional study that influences the primary outcome in this study. This may not apply to comparative effectiveness studies evaluating treatments that are available and used as part of clinical practice. Such cases will be adjudicated by the Concurrent Research Committee and Protocol Subcommittee.
    • Plan to deliver at a non-participating site
    • Participation in this trial in a previous pregnancy

Other illness

  • Known allergy or hypersensitivity to both labetalol and nifedipine ER
  • Severe hypertension defined as new onset systolic blood pressure ≥ 160 or diastolic blood pressure ≥ 110 on two occasions at least 4 hours apart (unless antihypertensive medication is initiated before this time) on or after 20 weeks 0 days gestation.

Lab values

  • High-risk co-morbidities for which treatment at a lower blood pressure level (i.e., below the standard cutoff of 160/110) may be indicated
    • Chronic kidney disease including any of the following lab values prior to 20 weeks gestation: proteinuria ≥ 300mg/24 hr, clean catch protein creatinine ratio ≥ 0.3, or serum creatinine \>1.1
    • Cardiac disorders including cardiomyopathy, angina, and coronary artery disease
    • Prior stroke
    • Retinopathy
    • Sickle cell disease
    • Preeclampsia with severe features defined as any of the following:
  • Severe features of preeclampsia as evidenced by end organ damage defined as any of the following on or after 20 weeks 0 days gestation:
    • Thrombocytopenia defined as a platelet count \<100,000
    • Renal insufficiency defined as a serum creatinine \>1.1 mg/dL or a doubling of the concentration in the absence of other renal disease
    • Impaired liver function defined as an elevated blood concentration of liver transaminases to twice normal concentration, or by severe persistent right upper quadrant or epigastric pain
    • Pulmonary edema
    • New onset headache unresponsive to medication and not accounted for by alternative diagnoses
    • Visual disturbances

Who the study is looking for

  • Singleton or di-chorionic twin gestation.
  • Gestational age at randomization from 23 weeks 0 days through 35 weeks 6 days based on clinical information and evaluation of the earliest ultrasound
  • Diagnosis of gestational hypertension or preeclampsia without severe features within 10 days prior to randomization.
    • Gestational hypertension or preeclampsia is defined as new onset systolic blood pressure 140-159 or diastolic blood pressure 90-109 (or both) on two occasions at least four hours apart on or after 20 weeks 0 days gestation with normal end-organ labs, with or without proteinuria.
    • Blood pressure measurements used for the diagnosis must occur during a formal clinical assessment in the outpatient, inpatient, or emergency care setting and be documented in the medical record. The diagnosis is made on the date of the second qualifying blood pressure.
    • At least 1 elevated blood pressure (systolic blood pressure 140-159 and/or diastolic blood pressure 90-109) must be documented at the recruitment site

Age in the registry: 14 years to 56 years · Sex: Female · Accepts healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (14)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
University of Alabama Birmingham
Coordinator of this site? Confirm its status
BirminghamUnited StatesUnknown status
University of North Carolina, Chapel Hill
Coordinator of this site? Confirm its status
Chapel HillUnited StatesUnknown status
Northwestern University
Coordinator of this site? Confirm its status
ChicagoUnited StatesUnknown status
Case Western Reserve University
Coordinator of this site? Confirm its status
ClevelandUnited StatesUnknown status
Ohio State University
Coordinator of this site? Confirm its status
ColumbusUnited StatesUnknown status
Duke University
Coordinator of this site? Confirm its status
DurhamUnited StatesUnknown status
University of Texas Houston
Coordinator of this site? Confirm its status
HoustonUnited StatesUnknown status
Baylor College of Medicine
Coordinator of this site? Confirm its status
HoustonUnited StatesUnknown status
Columbia University
Coordinator of this site? Confirm its status
New YorkUnited StatesUnknown status
University of Pennsylvania
Coordinator of this site? Confirm its status
PhiladelphiaUnited StatesUnknown status
Magee - Women's Hospital
Coordinator of this site? Confirm its status
PittsburghUnited StatesUnknown status
Brown Univeristy
Coordinator of this site? Confirm its status
ProvidenceUnited StatesUnknown status
University of Utah
Coordinator of this site? Confirm its status
Salt Lake CityUnited StatesUnknown status
Regents of the University of California San Francisco
Coordinator of this site? Confirm its status
San FranciscoUnited StatesUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.